Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in Cell Factories

Gene Therapy

Volumn 13, Issue 1, 2006, Pages 95-100

  Przybylowski, M ^a   Hakakha, A ^a   Stefanski, J ^a   Hodges, J ^a   Sadelain, M ^a   Riviere I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Clinical grade retrovial vector; Scale up; Validation; Vector safety

Indexed keywords

LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

ARTICLE; CELL LINE; CONTAMINATION; HUMAN; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; PRODUCTIVITY; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS TITRATION;

ANIMALS; BIOREACTORS; BIOTECHNOLOGY; CELL SEPARATION; FREEZING; GENE THERAPY; GENETIC VECTORS; HUMANS; INDUSTRY; PLASMIDS; QUALITY CONTROL; RETROVIRIDAE;

ANIMALIA; LENTIVIRUS; PRIMATES;

EID: 29244443951     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302648     Document Type: Article

References (18)

1. US Food and Drug Administration Center for Biologics Evaluation and Research. Points to Consider in the Production and Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology. Rockville, MD, 1985.
2. Kotani H, Newton PB, Zhang S, Chiang YL, Otto E, Weaver L et al. Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther 1994; 5: 19-28.
3. Sheridan PL, Bodner M, Lynn A, Phuong TK, DePolo NJ, de la Vega Jr DJ et al. Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: Improved safety and high titer. Mol Ther 2000; 2: 262-275.
4. Merten O-W, Cruz PE, Rochette C, Geny-Fiamma C, Bouquet C, Goncalves D et al. Comparison of different bioreactor systems for the production of high titer retroviral vectors. Biotechnol Progr 2001; 17: 326-335.
5. Pan D, Whitley CB. Closed hollow-fiber bioreactor: A new approach to retroviral vector production. J Gene Med 1999; 1: 433-440.
6. Eckert HG, Kuhlcke K, Schilz AJ, Lindemann C, Basara N, Fauser AA et al. Clinical scale production of an improved retroviral vector expressing the human multidrug resistance 1 gene (MDR1). Bone Marrow Transplan 2000; 25: S114-S117.
7. Schilz AJ, Kuhlcke K, Fauser AA, Eckert HG. Optimization of retroviral vector generation for clinical application. J Gene Med 2001; 3: 427-436.
8. Reeves L, Cornetta K. Clinical retroviral vector production: Step filtration using clinically approved filters improves titers. Gene Therapy 2000; 7: 1993-1998.
9. Miller AD, Garcia JV, von Suhr N, Lynch CM, Wilson C, Eiden MV. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 1991; 65: 2220-2224.
10. Wikstrom K, Blomberg P, Islam KB. Clinical grade vector production: analysis of yield, stability, and storage of GMP-produced retroviral vectors for gene therapy. Biotechnol Progr 2004; 20: 1198-1203.
11. Gallardo HF, Tan C, Sadelain M. The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes. Gene Therapy 1997; 4: 1115-1119.
12. Koehne G, Gallardo HF, Sadelain M, O'Reilly RJ. Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood 2000; 96: 109-117.
13. Gallardo HF, Tan C, Ory D, Sadelain M. Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudo-transduction in human peripheral blood lymphocytes. Blood 1997; 90: 952-957.
14. MacNeill EC, Hanenberg H, Pollok KE, van der Loo JC, Bierhuizen MF, Wagemaker G et al. Simultaneous infection with retroviruses pseudotyped with different envelope proteins bypasses viral receptor interference associated with colocalization of gp70 and target cells on fibronectin CH-296. J Virol 1999; 73: 3960-3967.
15. US Food and Drug Administration Center for Biologics Evaluation and Research. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. Rockville, MD, 1997.
16. Slepushkin V, Chang N, Cohen R, Gan Y, Jian B, Deausen E et al. Large-scale purification of a lentiviral vector by size exclusion chromatography or Mustang Q ion exchange capsule. Bioprocess J 2003; 2: 89-95.
17. US Food and Drug Administration Center for Biologics Evaluation and Research. Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals. Rockville, MD, 1993.
18. US Food and Drug Administration Center for Biologics Evaluation and Research. Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy. Rockville, MD, 1998.